The AI Change That Let Pfizer's Albert Bourla Sleep Better
- Pfizer CEO admits to restless nights over lackluster AI integration
- Company struggling to translate hype into actual bottom-line results
- Bourla pivots to 'AI-first' strategy in desperate bid for efficiency
- Corporate boardroom obsession with machine learning reaches fever pitch
Brief Summary
Pfizer CEO Albert Bourla has bared his soul—or at least his insomnia—revealing that the slow rollout of artificial intelligence within the pharmaceutical giant has been keeping him up at night. Despite the industry-wide rush to sprinkle 'AI' on every balance sheet, the results at Pfizer apparently weren't meeting the high-stakes expectations of the corner office.
Why This Matters
When a pharmaceutical behemoth struggles to harness technology, it signals a massive shift in how drugs are developed and priced. If these companies successfully automate R&D, you might see faster breakthroughs or, more likely, a consolidation of power that keeps costs high while tech replaces human oversight. Watch closely as these giants bet their future on algorithms, because it will fundamentally change how your medicine is discovered and manufactured.